Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RTSL's EV-to-OCF is not ranked *
in the Diversified Financial Services industry.
Industry Median: -32.96 * Ranked among companies with meaningful EV-to-OCF only.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Rapid Therapeutic Science Laboratories's PE Ratio (TTM) for today is calculated as:
Rapid Therapeutic Science Laboratories's share price for today is $0.0001.
Rapid Therapeutic Science Laboratories's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.010.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Rapid Therapeutic Science Laboratories EV-to-OCF Related Terms
Rapid Therapeutic Science Laboratories EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Shell Companies subindustry, Rapid Therapeutic Science Laboratories's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rapid Therapeutic Science Laboratories EV-to-OCF vs Diversified Financial Services Industry
For the Diversified Financial Services industry and Financial Services sector, Rapid Therapeutic Science Laboratories's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Rapid Therapeutic Science Laboratories's EV-to-OCF falls into.
Rapid Therapeutic Science Laboratories's current Enterprise Value is $0.00 Mil.
Rapid Therapeutic Science Laboratories's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.57 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rapid Therapeutic Science Laboratories (RTSL) has a EV-to-OCF of -0.00 as of Aug. 16, 2026.
Is Rapid Therapeutic Science Laboratories' EV-to-OCF too high?
Rapid Therapeutic Science Laboratories' current EV-to-OCF is -0.00.
How does Rapid Therapeutic Science Laboratories' EV-to-OCF compare to VRAYQ and NNMX?
Rapid Therapeutic Science Laboratories' EV-to-OCF of -0.00 can be compared against companies in the Diversified Financial Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Diversified Financial Services company?
A good EV-to-OCF depends on the Diversified Financial Services industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Rapid Therapeutic Science Laboratories's current EV-to-OCF is -0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rapid Therapeutic Science Laboratories stock overvalued right now?
Rapid Therapeutic Science Laboratories (RTSL) has a current EV-to-OCF of -0.00. The current EV-to-OCF is -0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Rapid Therapeutic Science Laboratories (RTSL), the current EV-to-OCF is -0.00 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RTSL has been successfully added to your 
